Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.19 per share which beat the analyst consensus estimate of $0.09 by 111.11 percent. This is a 1050 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $21.281 million which beat the analyst consensus estimate of $20.579 million by 3.41 percent. This is a 82.72 percent increase over sales of $11.647 million the same period last year.